Atea Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Other than as disclosed below, during the three months ended September 30, 2024, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted orterminateda “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K.
On September 10, 2024, Maria Arantxa Horga, M.D., our Chief Medical Officer, terminated a Rule 10b5-1 trading arrangement, as defined in term 408(a) of Regulation S-K, that wasadopted on June 17, 2024 to sell 67,198 shares of the Company’s common stock thru June 15, 2025. No shares of the Company’s common stock were sold under this trading arrangement prior to the termination.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.